Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for…
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the…
Read More...
Read More...
Browsing Tag
Ensifentrine
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across…
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the…
Read More...
Read More...
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in…
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the…
Read More...
Read More...
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24…
Read More...
Read More...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for…
LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the…
Read More...
Read More...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for…
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the…
Read More...
Read More...
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society…
LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a…
Read More...
Read More...
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and…
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179…
Read More...
Read More...